Adicon Holdings (09860) closed up nearly 7%, rising 6.73% to HK$4.76 by the market close, with a turnover of HK$1.562 million. Earlier this month, the company formally entered into a strategic cooperation agreement with Gobi Medical Group. The two parties will establish a long-term, stable strategic partnership, focusing on diversified collaboration in areas such as medical and scientific research services, joint development platform construction, IT data coordination, and discipline development and talent cultivation. This strategic collaboration between Adicon and Gobi Medical Group represents a significant cross-sector integration between a third-party medical testing institution and a research-focused medical group, and is a key step for Adicon in deepening its integrated development path of "technology + service + ecosystem." Notably, following the full digestion of negative factors and the potential return of capital, Adicon Holdings is expected to begin a valuation recovery. In November 2025, Adicon Holdings announced the acquisition of Crown Bioscience for US$204 million. Its comparable company, BioMap, currently has a market capitalization of nearly HK$26 billion, indicating that Adicon's current market value does not fully reflect its reasonable valuation, leaving ample room for upward adjustment.